At the news
? NEUTRALIMPACT 5/10 8-K filed May 12, 2026 at 16:10 ET
Kura Oncology reported Q1 2026 results with $5.8M in KOMZIFTI product revenue (first full commercial quarter), beating consensus revenue estimates. However, the net loss widened to $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025, driven by increased R&D and SG&A costs for the commercial launch and clinical trials. The company maintains a strong cash position of $580.8M plus $180M in anticipated collaboration payments, funding operations into 2028.
- Q1 2026 net product revenue of $5.8M from KOMZIFTI, first full commercial quarter
- 85 new patient starts and 157 total prescriptions in Q1 2026
- Net loss of $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025
- Cash and investments of $580.8M as of March 31, 2026, down from $667.2M at year-end 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access